October 4, 2018 06:41 AM EDT
Financing
Deals

Black­stone bags Clarus, stak­ing out a grow­ing PhI­II niche for it­self in a rapid­ly chang­ing bio­phar­ma in­dus­try

John Carroll

Editor & Founder

Black­stone likes life sci­ences. And now it’s div­ing in deep.

The pri­vate eq­ui­ty gi­ant has com­plet­ed a deal to buy Clarus, a busy life sci­ences …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times